Tempus Labs, Inc. (commonly known as Tempus or Tempus AI, Inc. following its IPO) is a precision medicine and technology company focused on using artificial intelligence and data analytics to personalize cancer care and other areas of medicine. The company builds and operates a large-scale library of clinical and molecular data and provides decision-support tools to physicians and researchers.
Think of this as a super-powered microscope that doesnât just look at cancer cells, but reads their genetic âinstruction manualâ. AI helps doctors quickly spot the tiny DNA changes that define each personâs cancer and match them with the best-targeted treatments.
This is like giving doctors a super-smart assistant that has read millions of medical cases and guidelines, then quietly whispers, âHere are the likely diagnoses and what to check nextâ while the doctor is still seeing the patientâespecially to catch diseases earlier than usual.
Think of BC Catalyst as a super-smart librarian for hospitals and research labs: it safely connects and reads genetic, clinical, and other health data stored in many different places, then uses AI to help scientists and pharma companies quickly find the right patients and design better-targeted treatments.
This is about using very smart pattern-finding computers to read our genes and medical data so doctors can pick the right drug and dose for each person, instead of treating everyone the same.
This is like giving oncologists a super-assistant that can read many different kinds of medical information at onceâgenomic profiles, imaging, lab results, and clinical notesâand then suggest patterns, risks, and treatment options that would be hard for any one human to spot alone.